Cannabis and MS: How Medical Marijuana Helps Manage Spasticity

Spasticity — the painful muscle stiffness, spasms, and tightness — affects up to 80% of people with multiple sclerosis and is one of the most difficult symptoms to manage with conventional medications. Baclofen causes sedation, tizanidine causes liver problems, and botulinum toxin injections provide only localized relief. Cannabis for MS spasticity has the strongest clinical evidence of any neurological application outside epilepsy — including the approval of Sativex (nabiximols), a cannabis-derived mouth spray, in over 25 countries for MS spasticity. This guide covers what Florida MS patients need to know about using medical marijuana for spasticity management.

Why MS Causes Spasticity and How Cannabis Helps

Multiple sclerosis attacks the myelin sheath that insulates nerve fibers in the brain and spinal cord. When myelin is damaged, the nerve signals that control muscle tone become disrupted — instead of smooth, coordinated muscle contractions, muscles receive chaotic signals that cause them to tighten involuntarily. Spasticity can range from mild muscle stiffness to painful spasms that prevent sleep and mobility. The endocannabinoid system is deeply involved in regulating muscle tone. CB1 receptors in the spinal cord modulate the stretch reflex — the neural circuit that controls muscle tension. When CB1 receptors are activated by cannabinoids, they reduce the excessive neural firing that causes spastic muscle contractions. CB2 receptors on immune cells in the central nervous system reduce the neuroinflammation that drives ongoing myelin damage. This dual action — symptom relief through CB1 plus potential disease modification through CB2 — makes cannabis a uniquely promising therapy for MS. A study by Pryce et al. (Brain, 2015) demonstrated that endocannabinoid augmentation not only reduced spasticity in an MS animal model but also reduced neurodegeneration.

Clinical Evidence: The Sativex Trials and Beyond

The strongest evidence comes from the clinical trials of Sativex (nabiximols) — a standardized 1:1 THC:CBD oromucosal spray approved in 25+ countries for MS spasticity (though not yet in the U.S.). A Phase III RCT by Novotna et al. (European Journal of Neurology, 2011) enrolled 572 MS patients with spasticity resistant to conventional treatment. After a 4-week single-blind period, 42% of patients were classified as responders (≥20% improvement in spasticity). In the subsequent 12-week double-blind phase, responders who continued Sativex maintained their improvement while those switched to placebo deteriorated — demonstrating that the benefit was genuinely from cannabis, not placebo. A Cochrane systematic review by Filippini et al. (2022) analyzed all available RCTs of cannabinoids for MS and concluded there was moderate-certainty evidence that nabiximols reduced patient-reported spasticity and pain. The MUSEC trial (Zajicek et al., Journal of Neurology, Neurosurgery and Psychiatry, 2012) studied oral cannabis extract in 279 MS patients and found that the cannabis group was twice as likely to report symptom relief as placebo.

Best Products and Ratios for MS Spasticity

Based on the clinical evidence (particularly the Sativex trials), a 1:1 THC:CBD ratio is the best-supported formulation for MS spasticity. THC provides the primary antispastic effect through CB1 receptor activation in the spinal cord, while CBD adds anti-inflammatory neuroprotection and moderates THC's psychoactive effects. For Florida patients, the closest equivalent to Sativex is a 1:1 THC:CBD sublingual tincture — several dispensaries carry this formulation. Start with 2.5mg THC / 2.5mg CBD per dose, taken 2–3 times daily, and titrate up every 5–7 days until spasticity improves or side effects limit further increases. Most patients stabilize between 10–30mg THC / 10–30mg CBD per day. For breakthrough spasms (sudden, painful muscle contractions), vaporized cannabis provides faster relief than tinctures. Keep a vape pen with a balanced or indica-dominant cartridge accessible for spasm episodes. For nighttime spasticity that disrupts sleep, a slightly higher-THC formulation taken before bed can address both the spasms and the sleep disruption they cause.

Cannabis for Other MS Symptoms

MS is a multi-symptom disease, and cannabis addresses several symptoms simultaneously. Neuropathic pain affects up to 86% of MS patients. The same cannabinoid mechanisms that reduce spasticity also modulate pain signaling — many patients report that their pain improves alongside their spasticity with no need for separate pain management. Bladder dysfunction (urgency, frequency, incontinence) affects 75% of MS patients. The CAMS study (Zajicek et al., Lancet, 2003) found that cannabis significantly improved urinary urgency and incontinence in MS patients. CB1 receptors in the bladder detrusor muscle modulate contraction frequency. Fatigue is the most common MS symptom (80%+). While cannabis can cause drowsiness, low-dose balanced or sativa-dominant products during the day can actually improve energy and motivation. Sleep disruption, often caused by spasticity and pain, improves as these symptoms are treated with cannabis. Emotional changes (depression, pseudobulbar affect) are common in MS. Cannabis's mood-modulating effects can complement conventional treatments.

Cannabis and Disease-Modifying Therapies

MS patients on disease-modifying therapies (DMTs) like ocrelizumab, natalizumab, or dimethyl fumarate can generally use cannabis safely alongside these medications. There are no known direct pharmacological interactions between cannabis and the major MS DMTs. However, some considerations apply. Immunomodulation: CBD has anti-inflammatory and immunomodulatory properties. While this is potentially beneficial in MS (an autoimmune disease), there's theoretical concern about adding immunomodulation on top of immunosuppressive DMTs. In practice, the doses of CBD used for symptom management don't appear to meaningfully affect the immune suppression provided by DMTs. Liver monitoring: patients on DMTs that require liver function monitoring (like dimethyl fumarate or teriflunomide) should be aware that high-dose CBD can also affect liver enzymes. Your neurologist should include this consideration in routine blood work. Coordination with your MS neurologist: Dr. Stratt communicates with patients' neurologists to ensure cannabis therapy is integrated safely. Bring your current medication list and DMT schedule to your evaluation.

Practical Tips for MS Patients Using Cannabis

Motor impairment and fatigue create practical challenges. Use pre-filled vape cartridges or pump-spray tinctures rather than products requiring fine motor skills. Set alarms for consistent dosing times — fatigue and cognitive fog in MS can make it easy to forget doses. Keep a symptom diary tracking spasticity severity (0–10 scale), number of spasms, sleep quality, and cannabis dose. This data helps optimize your treatment over time. Consider the cumulative effect — cannabis for spasticity works best with consistent daily dosing, not sporadic use. Give any new product or dose at least 1–2 weeks before judging effectiveness. Heat sensitivity is common in MS (Uhthoff's phenomenon). Avoid vaporizing in hot environments, and store cannabis products away from heat. Some patients find that cannabis is more effective when combined with stretching or physical therapy — the muscle relaxation from cannabis enhances the effectiveness of PT exercises.

Getting Certified for MS in Florida

Multiple sclerosis is explicitly listed as a qualifying condition under Florida Statute 381.986. Bring your MS diagnosis documentation, neurologist records, current DMT and symptom medication lists, and any spasticity-specific assessments. Dr. Stratt has experience working with MS patients and will develop a cannabis recommendation that targets your specific symptom profile — whether spasticity is your primary concern or you're dealing with multiple MS symptoms simultaneously.